What is the recommended dosage and administration of intrarosa (estradiol) 6.5 mg vaginal insert for postmenopausal women with moderate to severe dyspareunia or vulvar and vaginal atrophy?

INTRAROSA (Prasterone) 6.5 mg Vaginal Suppository Dosage

The recommended dosage of INTRAROSA (prasterone/DHEA) is one 6.5 mg vaginal insert administered intravaginally once daily at bedtime for the treatment of moderate to severe dyspareunia or vulvar and vaginal atrophy in postmenopausal women. 1, 2

Standard Dosing Regimen

• Administer one 6.5 mg vaginal insert once daily at bedtime – this is the FDA-approved dose that demonstrated significant improvement in dyspareunia severity, vaginal pH, and cellular maturation indices in phase III trials 1

• Continue daily administration without cycling or interruption – unlike some vaginal estrogen products that use intermittent dosing, prasterone requires consistent daily use for optimal efficacy 1, 2

• No dose titration is required – the 6.5 mg dose is both the starting and maintenance dose, with beneficial effects evident within 12 weeks and sustained through 52 weeks of treatment 1

Administration Instructions

• Insert the suppository as deeply as comfortable into the vagina using the applicator provided – proper placement ensures adequate tissue contact and dissolution 1

• Administer at bedtime to minimize leakage and maximize tissue contact time – this timing allows the product to remain in contact with vaginal tissues during sleep 1

• The suppository dissolves rapidly after insertion – no removal is necessary, and the formulation is designed for complete vaginal absorption 1

Clinical Efficacy Timeline

• Symptom improvement typically becomes evident within 4–6 weeks, with optimal benefit achieved by 12 weeks of consistent daily use 1, 2

• The total severity score of dyspareunia decreased by 1.27 to 1.63 units from baseline in clinical trials, representing clinically meaningful improvement 2

• Vaginal dryness severity decreased by 1.44 to 1.58 units from baseline, with improvements maintained through 52 weeks of treatment 2

• Parabasal cells decreased and superficial cells increased significantly, indicating restoration of vaginal epithelial maturation 1

Safety Profile and Systemic Absorption

• Serum concentrations of DHEA metabolites (estrogens and androgens) remain within normal postmenopausal ranges despite daily administration, indicating minimal systemic absorption 1

• The most common adverse event is vaginal discharge (application site discharge), which is generally mild and does not require discontinuation 1

• No endometrial proliferation or safety concerns were identified during 52 weeks of continuous treatment in phase III trials 1

Special Considerations for Breast Cancer Survivors

• Prasterone may be considered for women with hormone-positive breast cancer on aromatase inhibitors who have not responded to non-hormonal treatments (moisturizers, lubricants) after a thorough risk-benefit discussion with the oncology team 3, 4

• Limited supportive data exists for prasterone use in women with a history of cancer or on endocrine therapy, so the risk-benefit profile is not fully established in this population 5, 4

• The National Comprehensive Cancer Network recommends starting with non-hormonal options first (vaginal moisturizers 3–5 times weekly plus water-based lubricants during sexual activity) before escalating to prasterone 3, 4

Comparative Efficacy

• Daily 6.5 mg prasterone appears at least as efficacious as 0.3 mg conjugated estrogens or 10 μg estradiol for treatment of vulvovaginal atrophy symptoms, based on head-to-head comparison of clinical trial data 2

• Prasterone offers the advantage of addressing both estrogenic and androgenic deficiency that occurs after menopause, potentially providing broader symptom relief than estrogen-only products 1, 2

Common Pitfalls to Avoid

• Do not use intermittent or cyclic dosing – unlike some vaginal estrogen products, prasterone requires daily administration without breaks for optimal efficacy 1

• Do not discontinue prematurely if symptoms persist at 2–4 weeks – full therapeutic benefit requires 12 weeks of consistent daily use 1

• Do not assume prasterone is contraindicated in all breast cancer survivors – while caution is warranted, it may be an option for aromatase inhibitor users who have failed non-hormonal treatments after appropriate oncology consultation 3, 4